Think It's Too Late to Buy Tempus AI Stock? Here's the Biggest Reason Why There's Still Time.

Core Viewpoint - Tempus AI has experienced a significant stock price increase of nearly 99% since the beginning of 2023, but there remains potential for further growth due to strategic acquisitions and strong revenue retention metrics [1][2]. Company Developments - The recent acquisition of Ambry Genetics allows Tempus AI to enhance its cancer screening capabilities and expand into additional healthcare sectors such as pediatrics, reproductive health, and immunology [3]. - In 2023, Tempus AI reported a net revenue retention rate of 125%, indicating strong customer engagement and potential for future growth [4]. Financial Projections - Management forecasts 2024 revenue of $700 million, excluding Ambry's contributions, which would represent a 32$50 million from 2023 is anticipated [5]. Investment Considerations - Despite the stock's high-risk nature, there is still an opportunity for growth investors to consider investing in Tempus AI, although it is advised that only those comfortable with higher risk should proceed [6].